ArticleBMC psychiatry2026
Neuroimmune dysregulation and comorbidity mechanisms of major depressive disorder and migraine.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Single-cell RNA-sequencing reveals cellular heterogeneity and identifies biomarkers for obstructive sleep apnea and migraine.Human genomics · 2026Article
- Peripheral Immune and Metabolic Dysregulation in Migraine, Ménière's Disease, and Vestibular Migraine: A Single-Cell Atlas Study.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAlthough major depressive disorder (MDD) and migraine often present together, their comorbidity mechanisms are complex. This study aims to identify potential biomarkers and common mechanisms of MDD-migraine through neuroimmune microenvironment and transcriptome data, which is crucial for understanding its pathogenesis and developing diagnostic and treatment strategies.
methodsWe constructed a dynamic atlas of neural-peripheral immune cells in patients experiencing a MDD-migraine comorbidity. Differentially expressed genes (DEGs) were identified and performed functional enrichment and metabolic analyses of cell types involved in MDD and migraine. Multiple classification models were built by combining single-nucleus RNA sequencing and transcriptome data from patients with MDD to screen hub genes. In addition, cluster, cell communication, and trajectory analyses of major cell types in migraine were performed. Finally, common pathways in MDD-migraine comorbidity were identified.
resultsWe identified 60,982 and 22, 523 cells in patients with MDD and migraine, respectively. The proportions of oligodendrocytes and excitatory neurons were increased in the MDD group, while that of T cells was significantly increased in the migraine group. DEGs in the MDD and migraine cell types were associated with Rap1 signaling. Metabolic reprogramming was found to involve in the pathological processes of MDD and migraine. Six hub genes were screened using the optimal model: AHI1, NRCAM, PTMA, RABGAP1L, RPL15, and RPL41. T cells were the major cell subpopulation in migraine, and Naive T cells were the starting point of differentiation. Finally, eight common pathways were identified between MDD and migraine.
conclusionThis study provides new insights into the pathogenesis of MDD-migraine comorbidity suggesting that the identified key genes and signaling pathways may provide potential targets for the early diagnosis and treatment of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.